An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00809965 |
Recruitment Status :
Completed
First Posted : December 17, 2008
Results First Posted : June 2, 2014
Last Update Posted : September 17, 2014
|
Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator:
Bayer
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Coronary Syndrome Myocardial Infarction Myocardial Ischemia Unstable Angina | Drug: Rivaroxaban 2.5 mg Drug: Rivaroxaban 5 mg Drug: Placebo Drug: Standard of care | Phase 3 |
Acute coronary syndrome (ACS) is a serious and life threatening condition. Following an acute coronary syndrome event patients are at risk of important additional clinical events such as death, myocardial infarction, and stroke. Six months after patients present with an index event of ST-segment myocardial infarction, approximately 15% will either have died or had another episode of myocardial ischemia, and a similar situation exists for non-ST-segment elevation myocardial infarction/unstable angina patients. This randomized; double-blind; placebo controlled study will evaluate the efficacy and safety of rivaroxaban in addition to standard care in patients with a recent ACS. Patients will be given rivaroxaban (2.5 mg twice daily or 5 mg twice daily) or placebo (twice daily) in addition to standard care.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15526 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | September 2011 |
Actual Study Completion Date : | September 2011 |
Resource links provided by the National Library of Medicine

MedlinePlus related topics:
Heart Attack
Drug Information available for:
Rivaroxaban
Arm | Intervention/treatment |
---|---|
Experimental: Rivaroxaban 2.5 mg bid
One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
|
Drug: Rivaroxaban 2.5 mg
One tablet twice daily Drug: Standard of care |
Experimental: Rivaroxaban 5 mg bid
One 5 mg rivaroxaban tablet twice daily for up to 6 months
|
Drug: Rivaroxaban 5 mg
One tablet twice daily Drug: Standard of care |
Placebo Comparator: Placebo
One placebo tablet twice daily for up to 6 months
|
Drug: Placebo
One placebo tablet twice daily Drug: Standard of care |
Primary Outcome Measures :
- The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke [ Time Frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6) ]The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Secondary Outcome Measures :
- The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke [ Time Frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6) ]The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
- The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery [ Time Frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6) ]The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
- The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization [ Time Frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6) ]The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
- The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization [ Time Frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6) ]The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must be currently receiving aspirin therapy alone or in combination with a thienopyridine per national or local dosing recommendation
- Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital
Exclusion Criteria:
- Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding
- Need for continued anticoagulant therapy
- Significant renal impairment or known significant liver disease
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00809965
Locations


United States, Alabama | |
Birmingham, Alabama, United States | |
Geneva, Alabama, United States | |
Mobile, Alabama, United States | |
United States, California | |
Anaheim, California, United States | |
Burbank, California, United States | |
Los Angeles, California, United States | |
Mission Hills, California, United States | |
San Diego, California, United States | |
United States, Colorado | |
Aurora, Colorado, United States | |
Littleton, Colorado, United States | |
United States, Florida | |
Jacksonville, Florida, United States | |
Jupiter, Florida, United States | |
Kissimmee, Florida, United States | |
Miami, Florida, United States | |
Ocala, Florida, United States | |
Orlando, Florida, United States | |
Ormond Beach, Florida, United States | |
St Petersburg, Florida, United States | |
St. Petersburg, Florida, United States | |
United States, Georgia | |
Columbus, Georgia, United States | |
Rome, Georgia, United States | |
United States, Illinois | |
Aurora, Illinois, United States | |
United States, Indiana | |
Indianapolis, Indiana, United States | |
Merrillville, Indiana, United States | |
Munster, Indiana, United States | |
Valparaiso, Indiana, United States | |
United States, Kansas | |
Overland Park, Kansas, United States | |
Wichita, Kansas, United States | |
United States, Louisiana | |
Lacombe, Louisiana, United States | |
United States, Maryland | |
Bethesda, Maryland, United States | |
United States, Massachusetts | |
Boston, Massachusetts, United States | |
United States, Michigan | |
Flint, Michigan, United States | |
Grand Blanc, Michigan, United States | |
Grand Rapids, Michigan, United States | |
Kalamazoo, Michigan, United States | |
Mount Clemens, Michigan, United States | |
Petoskey, Michigan, United States | |
United States, Mississippi | |
Tupelo, Mississippi, United States | |
United States, Missouri | |
Saint Louis, Missouri, United States | |
United States, Montana | |
Kalispell, Montana, United States | |
United States, New Jersey | |
Bridgewater, New Jersey, United States | |
Linden, New Jersey, United States | |
United States, New York | |
Buffalo, New York, United States | |
Cortlandt Manor, New York, United States | |
Saratoga Springs, New York, United States | |
Stony Brook, New York, United States | |
Syracuse, New York, United States | |
United States, North Carolina | |
Winston Salem, North Carolina, United States | |
United States, Ohio | |
Cincinnati, Ohio, United States | |
Cleveland, Ohio, United States | |
Columbus, Ohio, United States | |
Dayton, Ohio, United States | |
Fairview Park, Ohio, United States | |
United States, Oklahoma | |
Bartlesville, Oklahoma, United States | |
Oklahoma City, Oklahoma, United States | |
United States, Pennsylvania | |
Doylestown, Pennsylvania, United States | |
Langhorne, Pennsylvania, United States | |
Ridley Park, Pennsylvania, United States | |
Sayre, Pennsylvania, United States | |
West Chester, Pennsylvania, United States | |
York, Pennsylvania, United States | |
United States, South Carolina | |
Greenville, South Carolina, United States | |
United States, Tennessee | |
Johnson City, Tennessee, United States | |
Memphis, Tennessee, United States | |
United States, Texas | |
Amarillo, Texas, United States | |
Lubbock, Texas, United States | |
Odessa, Texas, United States | |
Tomball, Texas, United States | |
United States, Utah | |
Salt Lake City, Utah, United States | |
United States, Vermont | |
Burlington, Vermont, United States | |
United States, Virginia | |
Danville, Virginia, United States | |
Roanoke, Virginia, United States | |
United States, Washington | |
Spokane, Washington, United States | |
United States, Wisconsin | |
Wausau, Wisconsin, United States | |
Argentina | |
Buenos Aires, Argentina | |
Cordoba, Argentina | |
Corrientes, Argentina | |
Junin, Argentina | |
La Plata, Argentina | |
Mar Del Plata, Argentina | |
Moron, Argentina | |
Morón, Argentina | |
Resistencia, Argentina | |
Rosario, Argentina | |
Salta, Argentina | |
San Luis, Argentina | |
Santa Fe, Argentina | |
Tucuman, Argentina | |
Australia | |
Bedford Park, Australia | |
Chermside N/A, Australia | |
Coffs Harbour South, Australia | |
Douglas, Australia | |
Epping, Australia | |
Fremantle, Australia | |
Heidelberg, Australia | |
Herston, Australia | |
Launceston, Australia | |
Milton, Australia | |
Newcastle, Australia | |
Parkville, Australia | |
Perth, Australia | |
Southport, Australia | |
Woolloongabba N/A, Australia | |
Belgium | |
Bonheiden, Belgium | |
Brussels, Belgium | |
Eupen, Belgium | |
Genk, Belgium | |
Huy, Belgium | |
Leuven, Belgium | |
Mol, Belgium | |
Tienen, Belgium | |
Brazil | |
Belo Horizonte, Brazil | |
Blumenau, Brazil | |
Campina Grande Do Sul, Brazil | |
Campinas, Brazil | |
Curitiba, Brazil | |
Porto Alegre, Brazil | |
Recife, Brazil | |
Ribeirao Preto, Brazil | |
Rio De Janeiro, Brazil | |
Salvador, Brazil | |
Sao Jose Do Rio Preto, Brazil | |
Sao Paulo, Brazil | |
São Paulo, Brazil | |
Bulgaria | |
Bourgas, Bulgaria | |
Dimitrovgrad, Bulgaria | |
Haskovo, Bulgaria | |
Pazardjik, Bulgaria | |
Pleven, Bulgaria | |
Plovdiv, Bulgaria | |
Rousse, Bulgaria | |
Sevlievo, Bulgaria | |
Sofia, Bulgaria | |
Varna, Bulgaria | |
Veliko Tarnovo, Bulgaria | |
Canada, Alberta | |
Edmonton, Alberta, Canada | |
Canada, British Columbia | |
Kelowna, British Columbia, Canada | |
Maple Ridge, British Columbia, Canada | |
Victoria, British Columbia, Canada | |
Canada, Newfoundland and Labrador | |
St. John'S, Newfoundland and Labrador, Canada | |
Canada, Ontario | |
London, Ontario, Canada | |
Newmarket, Ontario, Canada | |
Oshawa, Ontario, Canada | |
Ottawa, Ontario, Canada | |
Sudbury, Ontario, Canada | |
Canada, Quebec | |
Granby, Quebec, Canada | |
Montreal, Quebec, Canada | |
Quebec City, Quebec, Canada | |
Saint-Charles-Borromee, Quebec, Canada | |
Saint-Georges, Quebec, Canada | |
Sherbrooke, Quebec, Canada | |
Ste-Foy, Quebec, Canada | |
Canada, Saskatchewan | |
North Battleford, Saskatchewan, Canada | |
Canada | |
Laval, Canada | |
Chile | |
Antofagasta, Chile | |
Chile, Chile | |
Osorno X Región, Chile | |
Punta Arenas, Chile | |
San Bernardo, Chile | |
Santiago Rm, Chile | |
Santiago, Chile | |
Talcahuano, Chile | |
Temuco, Chile | |
Valdivia X Región, Chile | |
Victoria, Chile | |
Vina Del Mar, Chile | |
China | |
Beijing Prc, China | |
Beijing, China | |
Changsha, China | |
Daqing, China | |
Guangzhou, China | |
Hangzhou, China | |
Harbin, China | |
Jinan, China | |
Nanjing, China | |
Shanghai, China | |
Shen Yang, China | |
Shenyang, China | |
Tianjin, China | |
Xi'An, China | |
Colombia | |
Armenia, Colombia | |
Barranquilla, Colombia | |
Bogotá Dc, Colombia | |
Cali Valle Del Cauca, Colombia | |
Envigado, Colombia | |
Manizales, Colombia | |
Medellin, Colombia | |
Santander, Colombia | |
Croatia | |
Rijeka, Croatia | |
Slavonski Brod, Croatia | |
Suska 6, Croatia | |
Czech Republic | |
Benesov Nad Cernou, Czech Republic | |
Brno, Czech Republic | |
Ceske Budejovice, Czech Republic | |
Cesky Krumlov N/A, Czech Republic | |
Hradec Kralove, Czech Republic | |
Kolin N/A, Czech Republic | |
Kromeriz, Czech Republic | |
Litomysl, Czech Republic | |
Nachod N/A, Czech Republic | |
Pardubice N/A, Czech Republic | |
Plzeò 1, Czech Republic | |
Poruba, Czech Republic | |
Praha 10 N/A, Czech Republic | |
Praha 2, Czech Republic | |
Praha 8, Czech Republic | |
Praha, Czech Republic | |
Slany, Czech Republic | |
Teplice, Czech Republic | |
Usti Nad Labem, Czech Republic | |
Znojmo N/A, Czech Republic | |
Denmark | |
Aalborg, Denmark | |
Esbjerg, Denmark | |
Holbæk, Denmark | |
Horsens N/A, Denmark | |
Kolding, Denmark | |
København, Denmark | |
Odense, Denmark | |
Egypt | |
Alexandria, Egypt | |
Cairo, Egypt | |
Ismailia, Egypt | |
Menofeya, Egypt | |
France | |
Besancon, France | |
Cannes, France | |
Chambray-Les-Tours, France | |
Chartres, France | |
Creteil N/A, France | |
Dijon, France | |
Haguenau, France | |
Lagny, France | |
Marseille, France | |
Montfermeil, France | |
Paris, France | |
Poitiers, France | |
Germany | |
Bad Friedrichshall, Germany | |
Berlin, Germany | |
Bonn, Germany | |
Dresden, Germany | |
Essen, Germany | |
Esslingen, Germany | |
Frankfurt / Main, Germany | |
Freiburg, Germany | |
Greifswald, Germany | |
Göttingen, Germany | |
Halle, Germany | |
Hamburg, Germany | |
Hannover, Germany | |
Heidelberg, Germany | |
Kiel, Germany | |
Leipzig, Germany | |
Limburg, Germany | |
Lübeck, Germany | |
Magdeburg, Germany | |
Mannheim, Germany | |
Weiden, Germany | |
Wermsdorf, Germany | |
Witten, Germany | |
Greece | |
Athens, Greece | |
Larisa, Greece | |
Rhodes, Greece | |
Thessalonikis, Greece | |
Hungary | |
Budapest N/A, Hungary | |
Budapest, Hungary | |
Debrecen, Hungary | |
Győr, Hungary | |
Kecskemet, Hungary | |
Komarom, Hungary | |
Miskolc, Hungary | |
Szolnok, Hungary | |
Szombathely, Hungary | |
Zalaegerszeg, Hungary | |
India | |
Ahmedabad, India | |
Allahabad, India | |
Bangalore, India | |
Chandigarh, India | |
Chennai, India | |
Cochin, India | |
Coimbatore, India | |
Ernakulam, India | |
Gandhinagar Guiarat, India | |
Gurgaon, India | |
Hyderabad, India | |
Jaipur, India | |
Karamsad, India | |
Kochi, India | |
Kolkata, India | |
Lucknow Gpo, India | |
Ludhiana, India | |
Madurai, India | |
Mangalore, India | |
Mumbai, India | |
Mysore, India | |
Nagpur, India | |
Nasik, India | |
New Delhi, India | |
Pune, India | |
Surat, India | |
Trissur, India | |
Trivandrum, India | |
Vadodara, India | |
Vijayawada, India | |
Israel | |
Afula, Israel | |
Hadera, Israel | |
Haifa, Israel | |
Jerusalem, Israel | |
Nahariya, Israel | |
Petah Tikva, Israel | |
Rehovot, Israel | |
Safed, Israel | |
Tel Aviv, Israel | |
Tiberias, Israel | |
Japan | |
Anan, Japan | |
Fukui, Japan | |
Fukuoka-Shi,, Japan | |
Fukuyama-City,, Japan | |
Gifu-City, Japan | |
Higashiosaka-City, Japan | |
Kagoshima-City, Japan | |
Kanazawa-City, Japan | |
Kasuga, Japan | |
Kawachinagano-City, Japan | |
Kawasaki-City, Japan | |
Kisarazu-City, Japan | |
Kobe-City, Japan | |
Kobe-Shi, Japan | |
Kumamoto-City, Japan | |
Kumamoto, Japan | |
Kuwana-City, Japan | |
Maebashi-City Gunma, Japan | |
Matsudo-City, Japan | |
Matsumoto, Japan | |
Matsuyama-City Ehime, Japan | |
Miyazaki-Gun, Japan | |
Nagano-City, Japan | |
Nagasaki, Japan | |
Nagoya-City, Japan | |
Nagoya, Japan | |
Namegata-City, Japan | |
Nankoku-City, Japan | |
Nishinomiya, Japan | |
Okayama-City, Japan | |
Osaka-City, Japan | |
Osaka, Japan | |
Sakaide-City, Japan | |
Sakura-Shi, Japan | |
Suwa-City, Japan | |
Tokushima-City, Japan | |
Tokushima, Japan | |
Tokyo,, Japan | |
Tokyo, Japan | |
Toyama-City, Japan | |
Urasoe-City, Japan | |
Yamaguchi, Japan | |
Yokohama N/A, Japan | |
Yokohama-City, Japan | |
Yokohama-Shi, Japan | |
Yokohama, Japan | |
Yonago-Shi, Japan | |
Korea, Republic of | |
Daejeon, Korea, Republic of | |
Gwangju, Korea, Republic of | |
Seognam-Si, Kyungki-Do, Korea, Republic of | |
Seoul, Korea, Republic of | |
Suwon, Korea, Republic of | |
Latvia | |
Daugavpils, Latvia | |
Liepaja, Latvia | |
Riga, Latvia | |
Lithuania | |
Kaunas, Lithuania | |
Klaipeda, Lithuania | |
Siauliai, Lithuania | |
Vilnius Lt, Lithuania | |
Vilnius, Lithuania | |
Malaysia | |
Johor Bahru, Malaysia | |
Kelantan, Malaysia | |
Kota Samarahan, Malaysia | |
Kuala Lumpur, Malaysia | |
Selayang N/A, Malaysia | |
Mexico | |
Aguascalientes, Mexico | |
Cd. Juarez, Mexico | |
Ciudad De Mexico, Mexico | |
Culiacan, Mexico | |
Guadalajara, Mexico | |
Leon, Mexico | |
Mexico, Mexico | |
Monterrey, Mexico | |
Queretaro, Mexico | |
San Luis Potosi, Mexico | |
Sinaloa, Mexico | |
Veracruz, Mexico | |
Zapopan, Mexico | |
Morocco | |
Marrakech, Morocco | |
Meknès, Morocco | |
Rabat, Morocco | |
Netherlands | |
Amsterdam, Netherlands | |
Arnhem, Netherlands | |
Delft, Netherlands | |
Den Haag, Netherlands | |
Eindhoven, Netherlands | |
Gorinchem, Netherlands | |
Gouda, Netherlands | |
Haarlem, Netherlands | |
Harderwijk, Netherlands | |
Hengelo Ov, Netherlands | |
Nieuwegein, Netherlands | |
Nijmegen, Netherlands | |
Sittard, Netherlands | |
Vlaardingen, Netherlands | |
New Zealand | |
Auckland, New Zealand | |
Dunedin, New Zealand | |
Hamilton, New Zealand | |
Lower Hutt, New Zealand | |
Nelson, New Zealand | |
New Plymouth, New Zealand | |
Philippines | |
Iloilo City, Philippines | |
Marikina City, Philippines | |
Quezon City, Philippines | |
Poland | |
Bedzin, Poland | |
Białystok, Poland | |
Bielsko-Biala, Poland | |
Bydgoszcz, Poland | |
Bytom, Poland | |
Dąbrowa Górnicza, Poland | |
Gdynia, Poland | |
Gorlice, Poland | |
Katowice N/A, Poland | |
Katowice-Ochojec, Poland | |
Katowice, Poland | |
Koszalin, Poland | |
Krakow N/A, Poland | |
Krakow, Poland | |
Kutno, Poland | |
Lodz, Poland | |
Nowy Targ, Poland | |
Opole, Poland | |
Plock, Poland | |
Poznan N/A, Poland | |
Poznan, Poland | |
Ruda Slaska, Poland | |
Starogard Gdanski Nap, Poland | |
Szczecin N/A, Poland | |
Szczecin, Poland | |
Torun, Poland | |
Warszawa N/A, Poland | |
Warszawa, Poland | |
Wloclawek, Poland | |
Wroclaw, Poland | |
Zamosc, Poland | |
Portugal | |
Aveiro, Portugal | |
Braga, Portugal | |
Coimbra, Portugal | |
Faro, Portugal | |
Leiria, Portugal | |
Lisboa, Portugal | |
Penafiel, Portugal | |
Porto, Portugal | |
Vila Nova De Gaia, Portugal | |
Romania | |
Bucuresti, Romania | |
Craiova, Romania | |
Focsani, Romania | |
Oradea, Romania | |
Pitesti, Romania | |
Tg Mures, Romania | |
Timisoara, Romania | |
Russian Federation | |
Arkhangelsk, Russian Federation | |
Barnaul, Russian Federation | |
Chelyabinsk, Russian Federation | |
Ekaterinburg, Russian Federation | |
Ivanovo, Russian Federation | |
Kaliningrad, Russian Federation | |
Kemerovo, Russian Federation | |
Kirov, Russian Federation | |
Krasnodar, Russian Federation | |
Krasnoyarsk, Russian Federation | |
Kursk, Russian Federation | |
Lyubertsy, Russian Federation | |
Moscow N/A, Russian Federation | |
Moscow, Russian Federation | |
Nizhny Novgorod, Russian Federation | |
Novosibirsk, Russian Federation | |
Omsk, Russian Federation | |
Orenburg, Russian Federation | |
Penza, Russian Federation | |
Perm, Russian Federation | |
Pskov, Russian Federation | |
Pushkin, Saint-Petersburg, Russian Federation | |
Ryazan, Russian Federation | |
Saint-Petersbrug, Russian Federation | |
Saint-Petersburg, Russian Federation | |
Sestroretsk, Saint-Petersburg, Russian Federation | |
St Petersburg N/A, Russian Federation | |
St Petersburg, Russian Federation | |
St. Petersburg, Russian Federation | |
Syktyvkar, Russian Federation | |
Tomsk, Russian Federation | |
Tula, Russian Federation | |
Tumen Region, Russian Federation | |
Vladimir, Russian Federation | |
Voronezh, Russian Federation | |
Yaroslavl Nap, Russian Federation | |
Serbia | |
Belgrade, Serbia | |
Beograd, Serbia | |
Kragujevac, Serbia | |
Niska Banja, Serbia | |
Nis, Serbia | |
Slovakia | |
Bratislava, Slovakia | |
Nové Zámky, Slovakia | |
Zilina, Slovakia | |
Spain | |
Alicante N/A, Spain | |
Aviles Asturias, Spain | |
Barcelona, Spain | |
Burgos, Spain | |
Elche, Spain | |
Figueres, Spain | |
Guadalajara, Spain | |
Huelva N/A, Spain | |
Madrid, Spain | |
Malaga, Spain | |
Málaga, Spain | |
Salamanca, Spain | |
Santander, Spain | |
Sevilla, Spain | |
Tarragona, Spain | |
Valencia, Spain | |
Vigo, Spain | |
Sweden | |
Danderyd, Sweden | |
Göteborg, Sweden | |
Jönköping, Sweden | |
Linköping, Sweden | |
Lund, Sweden | |
Malmö, Sweden | |
Umeå, Sweden | |
Örebro, Sweden | |
Östersund, Sweden | |
Thailand | |
Bangkok, Thailand | |
Chiang Mai, Thailand | |
Pathumthani, Thailand | |
Phathumwan, Thailand | |
Tunisia | |
Sfax, Tunisia | |
Sousse, Tunisia | |
Tunis, Tunisia | |
Turkey | |
Ankara, Turkey | |
Aydin, Turkey | |
Bursa, Turkey | |
Erzurum, Turkey | |
Istanbul, Turkey | |
Izmir, Turkey | |
Kayseri, Turkey | |
Samsun, Turkey | |
Sivas, Turkey | |
Ukraine | |
Cherkassy, Ukraine | |
Dnepropetrovsk, Ukraine | |
Donetsk, Ukraine | |
Ivano-Frankivsk, Ukraine | |
Kharkov, Ukraine | |
Khemelnitskiy, Ukraine | |
Kiev, Ukraine | |
Lugansk, Ukraine | |
Lutsk, Ukraine | |
Lviv, Ukraine | |
Nikolaev, Ukraine | |
Poltava, Ukraine | |
Sumy, Ukraine | |
Ternopol, Ukraine | |
Uzhgorod, Ukraine | |
Vinnitsa, Ukraine | |
Zaporozhye, Ukraine | |
Zhytomir, Ukraine | |
United Kingdom | |
Birmingham, United Kingdom | |
Blackpool, United Kingdom | |
Bristol, United Kingdom | |
Chertsey, United Kingdom | |
Chesterfield, United Kingdom | |
East Sussex, United Kingdom | |
Exeter, United Kingdom | |
Hampshire, United Kingdom | |
Harrow, United Kingdom | |
Hull, United Kingdom | |
Leicester, United Kingdom | |
Lincoln, United Kingdom | |
Manchester, United Kingdom | |
Middlesbrough, United Kingdom | |
Portadown, United Kingdom | |
Stockport, United Kingdom | |
Warwick, United Kingdom | |
Worcester, United Kingdom |
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bayer
Investigators
Study Director: | Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
ClinicalTrials.gov Identifier: | NCT00809965 |
Other Study ID Numbers: |
CR014710 RIVAROXACS3001 ( Other Identifier: Johnson & Johnson Pharmaceutical Research and Development, L.L.C. ) |
First Posted: | December 17, 2008 Key Record Dates |
Results First Posted: | June 2, 2014 |
Last Update Posted: | September 17, 2014 |
Last Verified: | August 2014 |
Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Rivaroxaban Acute Coronary Syndrome ACS Aspirin Thienopyridine |
Unstable Angina Myocardial Infarction Anticoagulation Clopidogrel (Plavix) |
Additional relevant MeSH terms:
Myocardial Infarction Acute Coronary Syndrome Myocardial Ischemia Angina, Unstable Syndrome Infarction Ischemia Disease Pathologic Processes Necrosis Heart Diseases Cardiovascular Diseases Vascular Diseases |
Angina Pectoris Chest Pain Pain Neurologic Manifestations Rivaroxaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants |